# IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

> **NCT06713837** · PHASE3 · RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 339 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Relapse/Recurrence

## Interventions

- **DRUG:** High intensity therapies
- **DRUG:** Low intensity therapies

## Key facts

- **NCT ID:** NCT06713837
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 339 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06713837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06713837, "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06713837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*